This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Between 47-72% of patients diagnosed with multiple myeloma (MM) would be excluded from participating in clinical trials due to restrictive selection criteria. This is of particular interest in phase 3 trials, in which some clinical trials are focused on authorization approvals and other to serve as a mirror for real world clinical setting. Since 2017, the ASCO-Friends of Cancer Research published recommendations to modernize the inclusion criteria and favor the inclusion of patients in clinical trials.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.